Post job

Myriad Genetics CEO and executives

Executive Summary. Based on our data team's research, Paul J. Diaz is the Myriad Genetics's CEO. Myriad Genetics has 2,600 employees, of which 34 are in a leadership position.
Here are further demographic highlights of the leadership team:
  • The Myriad Genetics executive team is 41% female and 59% male.
  • 62% of the management team is White.
  • 10% of Myriad Genetics management is Hispanic or Latino.
  • 10% of the management team is Black or African American.
Work at Myriad Genetics?
Share your experience

Rate Myriad Genetics' leaders' effectiveness in guiding the company.

Zippia waving zebra
Name & TitleBio
Paul J. Diaz

CEO / President

Paul J. Diaz's LinkedIn

Paul J. Diaz, was named president, chief executive officer and member of the Myriad board of directors on August 13, 2020. Paul was most recently a partner at Cressey & Company (2016-2020), a private investment firm headquartered in Chicago, Illinois, which currently manages over $3.0 billion in committed capital. Cressey & Company is a healthcare focused middle-market private equity firm with over 30 years of success investing in and helping to build high quality healthcare businesses. Paul is the former president and chief executive officer and vice chairman of Kindred Healthcare, Inc. (NYSE:KND) (2002-2016) a Fortune 500 Company and one of the largest providers of healthcare services in the United States. At the time, Kindred had revenues of $7.2 billion, rehabilitation hospitals, sub-acute units, home health and hospice agencies and contract rehabilitation locations. For six years in a row, during his tenure as CEO, Kindred was ranked one of the Most Admired healthcare companies in the U.S. by Fortune magazine. Paul currently serves on the board of directors of DaVita (NYSE: DVA), the board of trustees of Johns Hopkins Medicine (where he serves as chair of Johns Hopkins Healthcare), and the board of visitors of the Georgetown University Law Center. He was formerly on the board of directors of PharMerica Corporation (NYSE: PMC), and previously served on the board of the Federation of American Hospitals, and the Bloomberg School of Public Health at John Hopkins University. While chief executive officer of Kindred, Paul was a member of the Business Roundtable and the Wall Street Journal CEO Council. Modern Healthcare magazine named Paul one of the 100 Most Influential People in Healthcare and named him one of the top 25 Minority Executives in Healthcare for numerous years. In addition, Hispanic magazine named Paul one of the 25 Best Latinos in business in multiple years. Paul earned a bachelor’s degree in Finance and Accounting from American University’s Kogod School of Business and a law degree from Georgetown University Law Center in Washington, D.C.

Walter Gilbert

Founder

Mark Skolnick

Founders

Peter Meldrum

Founders

Heinrich Dreismann

Board Member

Jerry S. Lanchbury Ph.d

Chief Scientific Officer

Jerry Lanchbury, chief scientific officer, joined Myriad in September 2002. Before that, he was a researcher in molecular immunogenetics at Kings College London. He is a highly respected expert in immunogenetics with more than 100 reviewed research journal publications. Dr. Lanchbury graduated from the University of Aston, Birmingham, U.K. He earned his Ph.D. in Population Genetics from the University of Newcastle upon Tyne and subsequently completed a postdoctoral fellowship at the United Medical & Dental Schools of the University of London in Human Disease Genetics.

Paul Chip Parkinson

Executive Vice President

R. Bryan Riggsbee

EVP Chief Financial Officer

R. Bryan Riggsbee's LinkedIn

Bryan Riggsbee, chief financial officer, joined Myriad in October 2014. He previously served 10 years with Laboratory Corporation of America (LabCorp) where his most recent position was as senior vice president of Corporate Finance with responsibility for the financial planning and analysis and treasury functions. Prior to LabCorp, Mr. Riggsbee served in various finance roles with General Electric and began his career in the audit division of KPMG. He received a B.A. degree in Accounting from North Carolina State University, a B.A. degree in Political Science from the University of North Carolina at Chapel Hill and an M.B.A. from Northwestern University. Mr. Riggsbee is a Certified Public Accountant licensed in the State of North Carolina.

S. Louise Phanstiel

Chairman

Clivetty Martinez Ph.d, Ccep

Chief Compliance Officer

Clivetty Martinez Ph.d, Ccep's LinkedIn

Clivetty Martinez, chief compliance officer, joined the company in 2019. Prior to Myriad, she served as senior vice president, chief compliance officer for Akorn Pharmaceuticals. She previously worked as vice president of compliance at Johnson & Johnson, Perrigo and director of compliance at Wyeth. Dr. Martinez received her Ph.D. in International Health Studies and has a master’s degree in Occupational Therapy from Duquesne University. She has compliance certifications for US, Europe and Latin America from Seton Hall, INSEAD University of Paris and University of Miami. She partnered with the University of Miami to develop the Executive Education in Compliance Program. She has been an international speaker on compliance topics and is considered a subject matter expert in her field. She is also member of the American College of Healthcare Executives, the Occupational Therapy Association and the American Business Women Association.

Do you work at Myriad Genetics?

Does the leadership team provide a clear direction for Myriad Genetics?

Myriad Genetics jobs

Myriad Genetics founders

Name & TitleBio
Walter Gilbert

Founder

Mark Skolnick

Founders

Peter Meldrum

Founders

Myriad Genetics board members

Name & TitleBio
Paul J. Diaz

CEO / President

Paul J. Diaz's LinkedIn

Paul J. Diaz, was named president, chief executive officer and member of the Myriad board of directors on August 13, 2020. Paul was most recently a partner at Cressey & Company (2016-2020), a private investment firm headquartered in Chicago, Illinois, which currently manages over $3.0 billion in committed capital. Cressey & Company is a healthcare focused middle-market private equity firm with over 30 years of success investing in and helping to build high quality healthcare businesses. Paul is the former president and chief executive officer and vice chairman of Kindred Healthcare, Inc. (NYSE:KND) (2002-2016) a Fortune 500 Company and one of the largest providers of healthcare services in the United States. At the time, Kindred had revenues of $7.2 billion, rehabilitation hospitals, sub-acute units, home health and hospice agencies and contract rehabilitation locations. For six years in a row, during his tenure as CEO, Kindred was ranked one of the Most Admired healthcare companies in the U.S. by Fortune magazine. Paul currently serves on the board of directors of DaVita (NYSE: DVA), the board of trustees of Johns Hopkins Medicine (where he serves as chair of Johns Hopkins Healthcare), and the board of visitors of the Georgetown University Law Center. He was formerly on the board of directors of PharMerica Corporation (NYSE: PMC), and previously served on the board of the Federation of American Hospitals, and the Bloomberg School of Public Health at John Hopkins University. While chief executive officer of Kindred, Paul was a member of the Business Roundtable and the Wall Street Journal CEO Council. Modern Healthcare magazine named Paul one of the 100 Most Influential People in Healthcare and named him one of the top 25 Minority Executives in Healthcare for numerous years. In addition, Hispanic magazine named Paul one of the 25 Best Latinos in business in multiple years. Paul earned a bachelor’s degree in Finance and Accounting from American University’s Kogod School of Business and a law degree from Georgetown University Law Center in Washington, D.C.

Heinrich Dreismann

Board Member

S. Louise Phanstiel

Chairman

Daniel K. Spiegelman

Board Member

Rashmi Kumar

Board Member

Colleen F. Reitan

Board Member

Daniel M. Skovronsky

Board Member

Lawrence Best

Board Member

Lee N. Newcomer

Board Member

Myriad Genetics leadership demographics

Myriad Genetics gender distribution in management team

  • The Myriad Genetics executive team is 41% female and 59% male.
  • Myriad Genetics is 44% female and 56% male company-wide.
Male
Male
59%
Company-wide: 56%
Female
Female
41%
Company-wide: 44%

Myriad Genetics executives by race

Management Team:
  • The most common ethnicity among Myriad Genetics executive officers is White.
  • 62% of the management team is White.
  • 16% of Myriad Genetics's management is Asian.
  • 10% of the management team is Hispanic or Latino.
Company-wide:
  • White is the most common ethnicity company-wide.
  • 71% of employees are White.
  • 12% of employees are Hispanic or Latino.
  • 9% of employees are Asian.
  • Management team
  • General
100%
80%
60%
40%
20%
0%
Unknown
White
Black or African American
Asian
Hispanic or Latino

Myriad Genetics jobs nearby

Myriad Genetics executives FAQs

Zippia gives an in-depth look into the details of Myriad Genetics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Myriad Genetics. The employee data is based on information from people who have self-reported their past or current employments at Myriad Genetics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Myriad Genetics. The data presented on this page does not represent the view of Myriad Genetics and its employees or that of Zippia.

Myriad Genetics may also be known as or be related to MYRIAD GENETICS INC, Myriad Genetics, Myriad Genetics Inc, Myriad Genetics Inc. and Myriad Genetics, Inc.